Protection from progressive renal failure and hyperparathyroid bone remodeling by WR-2721
- 1 May 1988
- journal article
- research article
- Published by Elsevier in Kidney International
- Vol. 33 (5) , 934-941
- https://doi.org/10.1038/ki.1988.90
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.Journal of Clinical Investigation, 1986
- Toxicity of Parathyroid Hormone in UremiaAnnual Review of Medicine, 1986
- Inhibition of parathyroid hormone secretion and parathyroid hormone-independent diminution of tubular calcium reabsorption by WR-2721, a unique hypocalcemic agent.Journal of Clinical Investigation, 1985
- SUPPRESSION OF PARATHYROID SECRETION AFTER ADMINISTRATION OF WR‐2721 IN A PATIENT WITH PARATHYROID CARCINOMAClinical Endocrinology, 1985
- Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells.Journal of Clinical Investigation, 1985
- Hypocalcemia and Inhibition of Parathyroid Hormone Secretion after Administration of WR-2721 (a Radioprotective and Chemoprotective Agent)New England Journal of Medicine, 1983
- Effect of Parathyroid Hormone on Osmotic Fragility of Human ErythrocytesJournal of Clinical Investigation, 1982
- Calcification in end-stage kidneysThe American Journal of Medicine, 1981
- Effect of parathyroid hormone on rat heart cells.Journal of Clinical Investigation, 1981
- SECONDARY HYPERPARATHYROIDISM AND RENAL OSTEO-DYSTROPHY IN CHRONIC RENAL FAILUREMedicine, 1969